Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
5 reports, 3 independent
Updated Aug 16
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty Pharma filed a prospectus with the Securities and Exchange Commission on September 3, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Royalty Pharma filed reports with the SEC while Morgan Stanley boosted its share position.1 source
Royalty Pharma filed a prospectus with the SEC.1 source
Keep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Bank of America raised holdings in Royalty Pharma, and Royalty Pharma filed a transaction with the SEC.
- Medpace filed required documents with the Securities and Exchange Commission on August 15, 2026.
- Quince Therapeutics plans to file its financial results with the Securities and Exchange Commission.
- Filings detail fund holdings for VGT with the Securities and Exchange Commission.
- Morgan Stanley was involved in market activity on the electronic stock exchange, with filings received regarding this activity.
Coverage
Newest first; wire copies grouped- tickerreport.com
- dailypolitical.com
- GlobeNewswireRoyalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offerin